Abbott Laboratories (NYSE:ABT) Shares Sold by Delta Asset Management LLC TN

Delta Asset Management LLC TN lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,723 shares of the healthcare product maker’s stock after selling 1,133 shares during the quarter. Delta Asset Management LLC TN’s holdings in Abbott Laboratories were worth $3,822,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Norges Bank purchased a new stake in Abbott Laboratories in the 4th quarter valued at about $2,115,836,000. Boston Partners grew its holdings in Abbott Laboratories by 12,577.8% in the fourth quarter. Boston Partners now owns 3,772,670 shares of the healthcare product maker’s stock valued at $415,948,000 after purchasing an additional 3,742,912 shares during the period. International Assets Investment Management LLC increased its position in Abbott Laboratories by 14,037.9% during the fourth quarter. International Assets Investment Management LLC now owns 1,349,176 shares of the healthcare product maker’s stock worth $148,504,000 after purchasing an additional 1,339,633 shares during the last quarter. Wellington Management Group LLP raised its stake in Abbott Laboratories by 4.3% during the third quarter. Wellington Management Group LLP now owns 31,208,711 shares of the healthcare product maker’s stock worth $3,022,564,000 after purchasing an additional 1,298,219 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Abbott Laboratories by 24.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,226,618 shares of the healthcare product maker’s stock valued at $575,304,000 after buying an additional 1,040,046 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity

In related news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now owns 78,704 shares of the company’s stock, valued at $9,444,480. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the sale, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 963 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $114,115.50. Following the completion of the sale, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at approximately $14,895,094.50. The disclosure for this sale can be found here. Insiders sold a total of 46,884 shares of company stock worth $5,153,916 in the last three months. 0.47% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Evercore ISI boosted their price target on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Citigroup cut their price target on shares of Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating on the stock in a report on Wednesday. Royal Bank of Canada dropped their price objective on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a research report on Thursday, April 18th. Barclays dropped their price target on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday, April 22nd. Finally, Raymond James restated a “buy” rating and set a $124.00 price target on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $120.60.

Abbott Laboratories Trading Up 1.8 %

Shares of ABT traded up $1.86 during midday trading on Wednesday, hitting $104.82. The stock had a trading volume of 5,932,132 shares, compared to its average volume of 5,649,579. The business has a 50-day simple moving average of $108.89 and a two-hundred day simple moving average of $109.54. The firm has a market cap of $182.35 billion, a P/E ratio of 32.64, a price-to-earnings-growth ratio of 2.48 and a beta of 0.76. The company has a current ratio of 1.60, a quick ratio of 1.11 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a fifty-two week low of $89.67 and a fifty-two week high of $121.64.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The company had revenue of $9.96 billion during the quarter, compared to analyst estimates of $9.88 billion. During the same quarter in the prior year, the company earned $1.03 earnings per share. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. As a group, equities analysts forecast that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.